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Background: The Lapinlahti 2005–2010 study was carried out to explore cardiovascular disease risk factors and
changes in lifestyle in Lapinlahti residents in eastern Finland. Our aim was to analyse factors influencing the level of
cholesterol in the community.
Methods: In 2005, 480 subjects aged 30–65 years underwent a complete health survey (baseline study) that
consisted of a structured questionnaire and a health examination. The follow-up was carried out five years later in
2010. The present study population included 326 individuals who did not use lipid-lowering medication at the
baseline. A trained research nurse measured weight, height, waist circumference and blood pressure at the
baseline and follow-up. Respectively, lifestyle factors (nutrition, exercise, smoking and alcohol use) were examined
with a structured questionnaire. Each lifestyle item was valued as −1, 0 or 1, depending on how closely it fitted to
the recommendations. Cholesterol level analyses at the baseline and follow-up were performed according to the
protocol of the Kuopio University Hospital’s medical laboratory. Based on their baseline cholesterol levels, the
participants were divided into tertiles. The age- and sex-adjusted linear trend between the tertiles was tested.
Results: The change in cholesterol level was associated with lipid-lowering medication (P < 0.001). Lifestyle
improvement was associated with the cholesterol level change but did not reach statistical significance (P = 0.061),
although the interaction of lipid-lowering medication and lifestyle change was associated with the change in
cholesterol level (P = 0.018). In multivariate analysis, a favourable change in fat consumption (P = 0.007) and
lipid-lowering medication (P < 0.001) were associated with decreasing cholesterol levels.
Conclusions: At the population level, dyslipidaemia is one of the most easily modifiable risk factors of CHD.
Lipid-lowering medication may have the most significant impact on cholesterol level in communities with primary
health care with good coverage. On the other hand, the potential of health-promoting and population-based
prevention strategies may be underused.
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Cardiovascular diseases, of which coronary heart disease
(CHD) is the most common, are the major cause of
death in most European countries [1]. Serum cholesterol
levels are linearly related to CHD mortality. Furthermore,
there is a linear relationship between the increase in CHD
mortality and an increase in cholesterol levels [2]. Evidence* Correspondence: Jorma.Savolainen@uef.fi
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indicates that dyslipidaemia is one of the most important
modifiable risk factors for CHD [3,4]. Cholesterol levels are
determined by multiple genetic factors as well as by envir-
onmental factors—primarily dietary habits [5]. According
to current clinical CHD treatment guidelines, prevention
should be based on an assessment of each individual’s
overall risk of atherosclerotic vascular diseases. If the risk
is significantly increased, it should be lowered through
lifestyle changes and/or medical treatment [6,7].
Finland has a long tradition of public health policies
with many health promotion programmes, of which the
North Karelian project (launched in 1972) in easterntral . This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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done in Finland has led to greatly improved quantity and
quality of dietary fat intake and a remarkable reduction in
blood cholesterol levels [8]. Serum cholesterol levels
declined markedly in Finland from 1972 to 2007, as did
CHD mortality among the middle-aged [9]. However,
according to the FINRISKI 2012 study, this decline in
serum cholesterol levels has levelled off and actually had
increased recently (1.7% in men and 3.1% in women during
2007–2012) [10].
Clinical trials in humans have shown that lowering the
level of serum cholesterol with diet or drugs (statins) de-
creases subsequent incidence of fatal or nonfatal CHD
[3]. Many large clinical trials have demonstrated that
statins substantially reduce cardiovascular morbidity and
mortality in both primary and secondary prevention
[6,8,11]. Modification of diet, especially reductions in
saturated fat and cholesterol, effectively reduce serum
cholesterol concentrations, but there is considerable
heterogeneity in individual responses to cholesterol-
lowering diets [12]. There is also evidence that statin
users seem to adopt a healthier lifestyle than non-statin
users. This may be because statin users are likely to be
repeatedly exposed to information from health profes-
sionals, and at the same time their high-risk lipid profile
necessitating regular intake of drugs may have wide-spread
favourable reflections on their health, but the precise
mechanism behind this association is unknown [11].
Primary care physicians play a key role in identifying
and treating dyslipidaemia patients. In each case, lifestyle
modification should play an integral role in the manage-
ment programme with additive pharmacologic therapy, if
required [13]. Most articles published in medical literature
documenting successes in lipid lowering originate from
large academic centres or very large, well-funded studies.
The challenge for community-based physicians is to put
these lipid-lowering guidelines, standards and strategies
into everyday medical practice [14]. The aim of the present
study was to analyse the population’s cholesterol level
changes during the five-year follow-up period in the
primary health care setting.
Methods
Lapinlahti, with a total population of 10289, is a typical
semi-rural municipality in eastern Finland with a
demographic shift to older age strata and increasing
migration of the young and economically active popu-
lation to urban centres [15]. All adults born in 1939,
−44, −49, −54, −59, −64, −69 and −74 living in Lapinlahti
municipality in Eastern Finland were included in the
original study sample based on the Finnish National
Population registry [16].
In 2005, 480 subjects (63% of the whole study popula-
tion230 men and 250 women) underwent a completehealth survey (baseline study) that consisted of a structured
questionnaire and a health examination [17]. After the
health check in 2005, all participants were sent a written
feedback by the researcher (physician). If necessary, it
included advice to e.g. quit smoking, decrease alcohol
use and to eat more vegetables, fruits and berries and
exercise more.
The present study is based on the five-year follow-up
of the baseline cohort (2005–2010) (N = 376, no. of
males = 184). Age, sex distribution, educational level,
marital status, employment status and BMI in subjects
who were lost from the follow-up or did not respond
were similar to those who were followed up. The use of
continuous medication was enquired at both examina-
tions. Those who had cholesterol-lowering medication in
2005 were excluded from these analyses. Hence, the
present study cohort included 326 individuals (no. of
males = 158).
The study participants filled out a structured question-
naire at both the baseline and follow-up. The questionnaire
included lifestyle items regarding smoking, alcohol use,
exercise and nutrition. Based on the national guidelines
and health recommendations [18,19], we ranked lifestyle as
follows: meal beverage (+1 = water or non-fat milk,
0 = skimmed milk or sour milk, −1 = fatty milk or
something else), cooking fat (+1 = nothing or margarine,
dairy spread, 0 = mixture of butter and vegetable oils,
−1 = butter or something else), spreads (+1 = nothing
or margarine spread, 0 =mixture of butter and vegetable
oils, −1 = butter or something else), cooking fat and
spreads were combined; use of vegetables (+1 = used more
than 6 times/week, 0 = used from 1 to 5 times /week,
−1 = never or occasional); berry and fruit intake (+1 = used
more than 6 times/week, 0 = from 1 to 5 times /week,
−1 = never or occasionally), vegetable, berry and fruit
intake (VBF) were also combined into a new variable
as was done with fats; adding salt to food (+1 = never,
0 = usually when food doesn’t taste salty enough, −1 = often
even without tasting); alcohol consumption (male: +1 = less
than 5 doses/week, −1 = over 5 doses/week or more,
female: +1 = less than 4 doses/week and −1 = 4 doses/week
or more); smoking (+1 = never smoking, −1 = regular or
irregular smoking); exercise (+1 = daily or more often,
0 = from 1 to 6 times /week, −1 = less than one time/
week). All these values were summed up and a mean
value (ranging from −1 to +1) was calculated for each
participant. The participants were divided into tertiles
(I = unhealthy, II = neutral and III = healthy) according to
the value of the sum score [20]. Figure 1 shows the distri-
bution of particular lifestyle scores and the distribution of
sum score. In addition, depressive symptoms were assessed
using the 21-item Beck Depression Inventory (BDI-21),
and a BDI-21 score of 10 was used as a cut-off point for
depressive symptoms [21].
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Figure 1 Distribution of the subjects in the particular lifestyle scores and in the lifestyle sum scores.
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follow-up included measurements of weight and height,
blood pressure and waist circumference. Weight was
measured in light clothing with a calibrated Camry®
standing scale to the nearest 0.1 kg, and height was mea-
sured in a standing position to the nearest 1.0 cm. Body
mass index (BMI) was calculated as weight/height2.
Waist circumference was measured at the midpoint be-
tween the lowest rib and the iliac crest. For the blood
pressure measurements, we used an Omron® M3 semi-
automatic device. Blood pressure was taken in a sitting
position at five-minute intervals after 10 minutes of rest.
For the statistical analysis, we calculated the means of
the three measurements.
All the laboratory investigations were performed accord-
ing to the protocol of the Kuopio University Hospital’s
medical laboratory and the values are based on the fasting
samples. Glucose level was tested from capillary blood
with a glucometer (HemoCue 201) calibrated for plasma
glucose level. Other laboratory tests were done from the
serum of venous blood. Lipid levels were measured with a
Cobas 6000 analyser as follows: plasma cholesterol by
using a colorimetric enzymatic assay, plasma high-density
lipoprotein (HDL) cholesterol by using a homogenous en-
zymatic colorimetric assay, plasma low-density lipoprotein
(LDL) cholesterol by using a homogenous enzymatic col-
orimetric assay and triglycerides by using an enzymatic
colorimetric test.
The data are presented as means and standard deviations
or as counts with percentages. Statistical comparisons were
made by using the chi-square test or analysis of variance
(ANOVA). In the case of violation of the assumptions (e.g.,on-normality), a bootstrap-type test was used. The boot-
strap method is significantly helpful when the theoretical
distribution of the test statistic is unknown or in case of
violation of the assumptions. To determine characteristics
associated with change in serum cholesterol levels, univari-
ate and forward stepwise multivariate regression analysis
was applied. No adjustment was made for multiple testing.
The STATA 13.1 (StataCorp LP, College Station, TX, USA)
statistical package was used for the analyses.
All the participants signed an informed consent form.
This study was carried out in compliance with the Helsinki
Declaration. Ethical permission for the study was granted
by the ethics committee of the Kuopio University Hospital
(number 129/2009).
Results
The demographic and clinical characteristics according
to serum cholesterol tertiles are presented in Table 1.
Gender distribution was equal across the tertiles. The
participants in the third tertile were older than in the
other tertiles. Higher education was more common in
the lowest cholesterol tertile than in the middle and
highest tertiles. Employment, living alone, BDI score,
smoking, alcohol consumption and physical activity did
not show a linear relationship with the serum cholesterol
tertiles. The proportions of subjects using medication
for blood pressure, diabetes or depression were similar
across the tertiles.
At the baseline, BMI, systolic and diastolic blood pres-
sure, LDL cholesterol level (in females and males), HDL
cholesterol level (only in females) and triglyceride levels
(in females and males) had a significant linear relationship
Table 1 Baseline characteristics of the study population
Total cholesterol at baseline P for linearity
<4.9 4.9–5.7 >5.7
N = 115 N = 106 N = 105
Number of females, % 64 (56) 58 (55) 46 (44) 0.16
Age, years, mean (SD) 47 (10) 51 (9) 53 (9) <0.001
Education years, mean (SD) 11.5 (3.0) 10.8 (2.8) 10.5 (2.8) 0.026
Living alone, n (%) 11 (10) 9 (9) 16 (15) 0.25
Employed, n (%) 81 (70) 67 (63) 62 (59) 0.20
Medication
Hypertension 15 (13) 16 (15) 25 (24) 0.084
Diabetes 7 (6) 2 (2) 2 (2) 0.13
Depression 3 (3) 0 (0) 2 (2) 0.27
BDI-211 score, mean(SD) 5.7 (7.3) 4.8 (4.9) 5.8 (6.3) 0.52
Smoking, n (%) 31 (27) 22 (21) 31 (30) 0.32
Alcohol use, n (%) 90 (78) 83 (78) 84 (80) 0.94
Physical activity, n (%) 0.44
Low 22 (19) 17 (16) 15 (14)
Moderate 36 (32) 25 (24) 32 (31)
High 55 (49) 64 (60) 57 (55)
121-Item Beck’s Depression Inventory.
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cholesterol levels in males, fasting plasma glucose and
hs-CRP had no relationship with total cholesterol
levels.
Table 2 also shows the absolute changes (from the
baseline to follow-up) in the aforementioned background
variables. There was a linear trend in HDL cholesterol
among males—the largest increase was seen in the lowest
cholesterol tertile. Respectively, in females, serum trigly-
ceride levels tended to decrease in the higher tertiles. A
significant relationship was found between diastolic blood
pressure changes and cholesterol tertiles.
The total number of subjects who started to use lipid-
lowering medication during the 5 years of follow-up was
64 (19.6%). There was a linear trend between the tertiles.
The percentages of subjects with initiated lipid-lowering
medication in the first, second and third tertiles were
7.8% (N = 9), 14.1% (N = 15) and 38.1% (N = 40), respect-
ively (age- and sex-adjusted p < 0.001). All lipid lowering
drugs were statins, simvastatin (mean dose 30 mg/day)
being the most common (81%).
The change in lifestyle was not associated with base-
line cholesterol levels (P = 0.76) or use of lipid-lowering
drugs (P = 0.89). Figure 2 presents the mean cholesterol
levels in the cholesterol tertiles at the baseline and the
change in cholesterol level after five years of follow-up
among subjects who had improved their lifestyle and
among those who had not. The results are reported sep-
arately for the individuals with lipid-lowering medicationand for those without. The difference between those
who had improved their lifestyle and those who did not
improve was significant only among subjects with medi-
cation in the highest baseline cholesterol tertile. The
cholesterol levels decreased among the subjects in the
highest tertile without lipid-lowering medication. Re-
spectively, cholesterol level decreased among the sub-
jects who used medication in the second and highest
tertiles. In general, the change in cholesterol level was
associated with medication (P < 0.001). Lifestyle improve-
ment was associated with the cholesterol level change, but
did not quite reach statistical significance (P = 0.061).
However, the interaction of lipid-lowering medication and
lifestyle change was associated with the cholesterol level
change (P = 0.018). Compared with total cholesterol, a
corresponding change was found in the LDL cholesterol
change. However, the corresponding findings for HDL
cholesterol and triglyceride changes were not significant.
A regression analysis included age, sex, baseline chol-
esterol, the particular components of lifestyle changes
(smoking, use of alcohol, physical activity, use of salt, use
of vegetables, fruits or berries and use of fat in meals) and
lipid-lowering medication (Table 3). In a univariate ana-
lysis age, baseline cholesterol level, lipid lowering medica-
tion and the favourable change in the use of fat in meals
were associated with the favourable change of cholesterol
level. In a multivariate forward stepwise method, baseline
cholesterol level, lipid lowering medication and change in
the use of fat in meals entered the model.
Table 2 Baseline clinical and biochemical characteristics and their changes (from baseline to follow-up)
Total cholesterol at baseline p for linearity
< 4.9 4.9–5.7 > 5.7
N = 115 N = 106 N = 105
Fasting Plasma cholesterol, mmol/L
Baseline 4.05 5.28 6.58 -
Change 0.53 (0.36 to 0.71) -0.29 (-0.43 to -0.14) -1.23 (-1.46 to -1.01) 0.14*
Body mass index, kg/m2
Baseline 26.2 (5.1) 27.4 (4.4) 28.6 (4.7) < 0.001
Change 0.59 (0.23 to 0.94) 0.29 (-0.09 to 0.066) 0.03 (-0.34 to 0.41) 0.42*
Fasting Plasma glucose, mmol/L
Baseline 5.50 (1.14) 5.48 (0.68) 5.47 (0.97) 0.41
Change 0.57 (0.34 to 0.80) 0.33 (0.09 to 0.57) 0.51 (0.27 to 0.75) 0.86*
Fasting Plasma LDL cholesterol, mmol/L
Males
Baseline 2.45 (0.55) 3.58 (0.32) 4.45 (0.64) < 0.001
Change 0.11 (-0.08 to 0.30) -0.58 (-0.75 to -0.40) -1.34 (-1.63 to -1.07) 0.47*
Females
Baseline 2.35 (0.47) 3.10 (0.45) 4.29 (0.66) < 0.001
Change 0.15 (-0.00 to 0.31) -0.37 (-0.52 to -0.21) -1.14 (-1.43 to -0.86) 0.21*
Fasting Plasma HDL cholesterol, mmol/L
Males
Baseline 1.05 (0.40) 1.14 (0.29) 1.11 (0.35) 0.45
Change 0.30 (0.22 to 0.37) 0.13 (0.05 to 0.21) 0.16 (0.09 to 0.23) 0.015*
Females
Baseline 1.27 (0.34) 1.45 (0.41) 1.44 (0.52) 0.026
Change 0.23 (0.15 to 0.31) 0.18 (0.09 to 0.26) 0.17 (0.07 to 0.26) 0.19*
Fasting Plasma triglycerides, mmol/L
Males
Baseline 1.12 (0.57) 1.33 (0.67) 1.81 (1.13) < 0.001
Change 0.07 (-0.18 to 0.31) 0.05 (-0.20 to 0.29) -0.09 (-0.31 to 0.14) 0.090*
Females
Baseline 0.88 (0.33) 1.22 (0.60) 1.59 (0.84) < 0.001
Change 0.14 (0.02 to 0.25) -0.12 (-0.24 to -0.01) -0.30 (-0.43 to -0.17) 0.025*
Blood pressure, mmHg
Systolic
Baseline 132 (20) 139 (17) 146 (18) < 0.001
Change 6.1 (3.1 to 9.1) 5.7 (2.6 to 8.9) 6.1 (3.0 to 9.2) 0.050*
Diastolic
Baseline 79 (11) 3 (10) 87 (11) <0.001
Change 2.2 (0.35 to 4.0) 1.3 (-0.6 to 3.2) 0.5 (-1.4 to 2.4) 0.036*
Baseline values as means (SD), change values as means with 95% CI.
*Adjusted for age, sex and baseline values.
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The present community and primary care setting findings
suggest that, at the population level, individual cardiovascu-
lar risk factor levels can be improved with lifestyle changesand use of drugs. A lowering of cholesterol levels was
achieved significantly among those people who used statins,
as expected, although a favourable change in lifestyle had at
least an additive influence on serum cholesterol level.
Serum cholesterol at baseline, mmol/L


































Change of lifestyle 
    No change or worsening
    Improvement
Serum cholesterol at baseline, mmol/L
<4.9 4.9-5.7  5.7
p=0.56p=0.93 p=0.013p=0.77p=0.62 p=0.30
Lipid lowering useNot lipid lowering use
Figure 2 Change in serum cholesterol level after the five-year follow-up period according to the baseline cholesterol levels in subjects
without and with lipid-lowering drugs.
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concentration and preventing ischemic heart disease
[22-24]. In dietary intervention studies, plasma lipid and
lipoprotein responses have been variable [25-29]. Yu-
Poth’s study shows that individuals with marked elevations
in total cholesterol and LDL cholesterol were less respon-
sive to dietary interventions than mildly to moderately hy-
percholesterolemic individuals. Supporting those findings,
our study indicated that higher cholesterol levels were not
associated with more significant lifestyle changes than
lower levels in general [30]. Lytsy et al. showed that pa-
tients taking statins seemed to have a healthier lifestyleTable 3 Association of age, gender, baseline cholesterol value
cholesterol level
Univariate
Variables β2 (95% CI)
Gender (Male) −0.12 (−0.26 to 0.01)
Age, years −0.27 (−0.40 to −0.14)
Total cholesterol at baseline, mmol/l −0.86 (−0.96 to −0.77)
Lipid-lowering medication −0.56 (−0.65 to −0.47)
Change of life style item:
Smoking 0.05 (−0.09 to 0.18)
Alcohol −0.08 (−0.21 to 0.06)
Exercise 0.06 (−0.07 to 0.20)
Berries and fruits 0.10 (−0.03 to 0.23)
Salt 0.01 (−0.13 to 0.14)
Use of fat in meals3 −0.19 (−0.32 to −0.06)
1Forward selection. Only those variables are shown that entered (significance level
2Standardized regression coefficients.
3Combined fats in meals, spreads and drinks.than non-statin users [11]. The present study did not find
this kind of trend. However, the present findings suggest
that favourable lifestyle changes are related to decreasing
cholesterol levels among statin users. It is possible that
need for daily chronic medication by some mechanisms
activates patients to make lifestyle changes.
The present study was based on a sample from one
community in a catchment of one primary health care
centre. In a community with active primary care, the most
significant factor behind a decreasing level of cholesterol
may be the use of cholesterol-lowering drugs. However,
the favourable change in fat consumption found in thes and particular lifestyle items with the change of
Multivariate1
P-value β2 (95% CI) P-value
0.067
<0.001
<0.001 −0.59 (−0.66 to −0.52) <0.001






0.006 −0.09 (−0.16 to −0.03) 0.007
for addition to the model was p < 0.05) the model.
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nity. It is probable that the potential of influencing the
health behaviour of individuals and the population in gen-
eral is not used as effectively as it could be [31]. Prescrib-
ing statins may be quite an easy intervention for a general
practitioner (GP). On the other hand, attempts to influ-
ence lifestyle and promote health can be more difficult,
although counselling delivered by the GP can be effective
[32]. In addition to intrapersonal factors, recognised
barriers to health promotion may include interpersonal,
institutional or community factors [31]. The traditional
biomedical model adopted by many physicians may result
in treatment rather than prevention. They may perceive a
lack of health promotion training and evidence about the
effectiveness of health-promoting actions [31]. In the
present study, cholesterol level changes were desirable
and related most strongly to lipid-lowering medication.
Contrary to these, BMI, plasma glucose and blood pres-
sure changes were not desirable. A trend towards positive
lifestyle changes seemed to have no impact on other
measures except lipids. The present results support the
view that, in addition to individual medical treatment,
population-based strategies have been sub-optimally adopted
in communities [33].
The study area—Lapinlahti municipality—represents a
semirural community. Therefore, these results may not
be directly generalised to more urban populations. How-
ever, primary health care in Finland has better popula-
tion coverage in rural and semirural areas than in urban
areas [34]. Hence, these results represent communities
with strong primary health care in which GPs have sig-
nificant potential to influence treatment and health be-
haviour. The information about nutrition components of
lifestyle was based on the structured questions but not
on a food diary. Therefore, we could assess general eat-
ing patterns but not intake of various food items. The
investigation focused on key risk factors and their
changes. The present study represents the general popu-
lation in one community. The measurements were con-
ducted in a similar way at the baseline and follow-up.
Likewise, lifestyle was measured in the same way at both
examinations. We did not have access to patient records.
Therefore we do not know the individual cholesterol
levels at the time point of starting lipid lowering medica-
tion. In general, the reasons for the initiation of treat-
ment in the Finnish primary health care followed the
national guidelines [35].
The impact of medication was obvious, because it was
started during the follow-up and evidently was in line
with the observed changes in serum cholesterol.
Conclusions
At the population level, dyslipidaemia is one of the most
easily modifiable risk factors of CHD. This study indicatesthat lipid-lowering medication may have the most signifi-
cant impact on cholesterol level in communities with pri-
mary health care with good coverage. On the other hand,
the potential of health-promoting and population-based
prevention strategies may be underused.
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